> All the big AIM fraud exposés
> 300 articles and podcasts a month
> Hot share tips
> Original investigations by our experienced team
> No ads, no click-bait, no auto-play videos
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Hello Share Movers. I have called your attention more than once to a firm called Advanced Oncotherapy (AVO). It is using the technology based on the Hadron Collider to develop a cancer treatment that is much cheaper and less bulky than older machines.
Whether or not you also climb on board is a matter for you, of course. But this is becoming an interesting situation – and worth talking about again on this tremendous web site.
Advanced has been in the news because it uses the kind of technology to treat cancer which the parents of that unfortunate lad with a brain tumour chose - and consequently hit the headlines so hard a few weeks ago.
There was a lot of related publicity about Advanced then and it shot the share price up from about 3p to 5.2p – a goodly jump. This week the shares are on the move again.
But there are one or two things about Advanced which possibly deserve an airing here.
For one thing the machines it makes are yet to be fully approved by everyone. The firm is not making money at the moment and all our hopes are on the future.
It seems to pay large wages and in any event this sort of venture costs a lot of development money. Presumably some of the many investments they have had from small investors is going towards that vital research.
The company says it already has £200 million of orders, which is good. And though losses are widening now, it could all be very different a few years down the line.
I have heard an interview with the company’s big cheese. He comes across well and he is very confident over progress so far.
Cancer, as we all know, is becoming even more of a problem, given that we are all living longer and have longer to develop it. So you may feel this is a good project to invest in, in the confident hope that it will ease some human suffering.
I think the share will probably stablise as news coverage dries until the next big development. But eventually I expect this share to blossom even more.
It’s being debated now in the Punter’s Return.
Malcolm Stacey has been writing about shares for more than 20 years. His first book "The Armchair Tycoon" was first published in 1998 but a revised 2014 e-version is now available. To obtain a FREE copy fill in the form HERE
Never miss a story.
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen